In a new paper published by the National Cancer Institute, a research team of six—including authors from federal agencies such as the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) and Food and Drug Administration (FDA)—turn a critical eye on cannabis regulatory systems in the United States, writing that administrative burdens stifle much-needed scientific investigation into the drug’s potential health applications and safety concerns. “Conflicting federal and state cannabis regulations hinder research in several ways,” says the article, published this month in the Journal of the National Cancer Institute Monographs, “including the inability of researchers to access products that are legal in their state, a lack of standardization and quality control of cannabis and cannabis-derived products within and across states, and no national oversight of this standardization and quality control or the industry.” “The most obvious regulatory hurdle in conducting cannabis and cannabinoid research is the schedule I status of cannabis.” With most states having legalized marijuana in some form, an array of new and relatively unstudied products have appeared on the consumer and medical markets, the authors write.

Ben Adlin, Marijuana Moment, 12/14/2021 14:24:00

Open article: